Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

Official title:

A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02448810
• Other study ID #: 391401
• Secondary ID: 2015-000896-28
• Status: Terminated
• Phase: Phase 2
• Start date: June 15, 2015
• Est. completion date: February 15, 2017

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy between BAX69 in combination with 5-FU/LV for subjects with KRAS or NRAS mutated tumor (mt) or panitumumab, for subjects with KRAS and NRAS wild type tumor (wt) and standard of care (SoC) per investigator choice as third or fourth treatment line in subjects with progressive measurable metastatic colorectal cancer (mCRC).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 115
• Est. completion date: February 15, 2017
• Est. primary completion date: February 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of a signed informed consent

2. Male and female subjects 18 years of age and older at the time of screening

3. Subjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment lines

4. Anticipated life expectancy >3 months at the time of screening

5. Weight between 40 kg and 180 kg

6. Histologically or cytologically confirmed diagnosis of CRC

7. Metastatic CRC not amenable to surgical resection

8. Known KRAS and NRAS mutation status (if unknown status for either of these genes, and no archival tissues is available, a fresh tumor biopsy will be made)

9. At least 1 measurable lesion as defined by RECIST v1.1

10. ECOG PS of 0-2

11. Adequate hematological function, defined as:

1. Platelet count = 100,000/µL

2. Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)

3. Absolute neutrophil count (ANC) = 1,000/µL

4. Hemoglobin = 9 g/dL, without the need for transfusion in the 2 weeks prior to screening

12. Adequate renal function, defined as serum creatinine = 2.0 times ULN and creatinine clearance > 50 mL/min

13. Adequate liver function, defined as:

1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)

= 2.5 times ULN for subjects without liver metastases, or = 5 times ULN in the presence of liver metastases

2. Bilirubin = 2.0 times ULN, unless subject has known Gilbert's syndrome

14. Adequate venous access

15. For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX69. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices

16. For male subjects, the subject must agree to use adequate contraceptive measures including at least 1 barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of BAX69

17. Subject is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

1. Known central nervous system metastases

2. Prior malignancy(s) within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer

3. Prior treatment with panitumumab for subjects with KRAS and NRAS wt tumor

4. Residual AE from previous treatment > Grade 1

5. Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor

6. Myocardial infarction within 6 months prior to C1D1, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)

7. Uncontrolled hypertension defined as systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg confirmed upon repeated measures

8. LVEF < 40% as determined by echocardiogram performed at screening or within 90 days prior to C1D1

9. QT/QTc interval > 450 msec, as determined by screening ECG performed no earlier than 1 week before C1D1

10. Prior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D1.

11. Major surgery within 4 weeks prior to C1D1

12. Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints

13. Active infection involving IV antibiotics within 2 weeks prior to C1D1

14. Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis

15. Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease

16. Subject has received a live vaccine within 4 weeks prior to C1D1

17. Known hypersensitivity to any component of recombinant protein production by CHO cells

18. Exposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study

19. Subject is nursing or intends to begin nursing during the course of the study

20. Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, ECG), that in medical judgment of the investigator may impede the subject's participation in the study, pose increased risk to the subject, and/or confound the results of the study

21. Subject is a family member or employee of the investigator

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Metastatic Colorectal Cancer

Intervention

Biological:
• BAX69 + infusional 5-FU/LV
Study Part 1: Safety Run-in Administered weekly as part of a 4 week treatment cycle Intravenous injection
• BAX69 + panitumumab
Study Part 1: Safety Run-in Administered weekly as part of a 4 week treatment cycle Intravenous injection
• BAX69 + 5-FU/LV
Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection
• BAX69 + panitumumab
Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection

Drug:
• Standard of Care
Investigator's choice Dose according to drug label

Biological:
• Standard of Care
Investigator's choice Dose according to drug label Choice includes panitumumab in KRAS &NRAS wt group only

Locations

Country	Name	City	State
United States	Montefiore Einstein Center for Cancer Care	Bronx	New York
United States	Medical University of South Carolina (MUSC)	Charleston	South Carolina
United States	Mary Crowley Cancer Research Center	Dallas	Texas
United States	The Jones Clinic, PC	Germantown	Tennessee
United States	Indiana University Health	Goshen	Indiana
United States	Joliet Oncology-Hematology Associates, Ltd.	Joliet	Illinois
United States	Mount Sinai Beth Israel	New York	New York
United States	University of Oklahoma Health Sciences Center	Oklahoma City	Oklahoma
United States	Hematology Oncology Associates of the Treasure Coast	Port Saint Lucie	Florida
United States	Maryland Oncology Hematology, P.A.	Rockville	Maryland
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	CTRC at University of Texas Health Science Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Baxalta now part of Shire

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 2: Progression-Free Survival (PFS)	PFS was defined as time between treatment initiation and tumor progression (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 criteria) or death from any cause, with censoring of participants who were lost to follow-up or withdrew consent.	From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression
Primary	Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT)	DLT was defined as any drug-related treatment-emergent adverse event (TEAE) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) that occurs during the first 28 days after treatment start and that meets any of the following criteria: i) Any >= Grade 3 non-hematologic toxicity (excluding: mucositis/stomatitis of Grade 3; diarrhea of <3 days duration; nausea and vomiting <3 days duration; fatigue of <7 days duration; alopecia; single laboratory value out of the normal range that has no clinical significance and that resolves to <= Grade 2 with adequate measures within 7 days) ii) Any Grade 4 hematologic toxicity (excluding: grade 4 neutropenia lasting for <= 5 days; isolated grade 4 lymphocytopenia) iii) Grade 3 febrile neutropenia iv) Grade 3 thrombocytopenia associated with bleeding v) Any life-threatening complication or abnormality not covered in NCI CTCAEv4.03.	From start of study treatment up to 28 days
Secondary	Number of Participants With Occurrence of Binding and/or Neutralizing Anti-imalumab Antibodies	Number of participants with occurrence of binding and/or neutralizing anti-imalumab antibodies were reported.	From start of study drug administration up to end of treatment (EOT) (approximately 21 Months)
Secondary	Number of Participants With Incidence of Infusion Reactions After Imalumab Administration	Infusion reaction was defined as any relevant sign or symptom occurring during or after imalumab infusion and considered by the investigator as an infusion reaction.	From start of study drug administration up to EOT (approximately 21 Months)
Secondary	Number of Participants With Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs)	An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any AE that results in any of the following outcomes: death, a life-threatening event, inpatient hospitalization or prolongation of an existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, other medically important events based upon appropriate medical judgement. TEAEs was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.	From start of study drug administration up to EOT (approximately 21 Months)
Secondary	Number of Participants With Response Evaluation According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1	Number of participants with response evaluation according to RECIST v1.1 was evaluated according to complete response (CR): disappearance of all target and non-target lesions and no new lesions; partial response (PR): >= 30 percent (%) decrease in the sum of diameters of target lesions (compared to baseline) and no new lesions; stable disease (SD): neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; progressive disease (PD): >= 20% increase in the sum of diameters of target lesions and an absolute increase in sum of diameters of >=5 millimeter (mm) (compared to the previous minimum sum) or progression of a new lesion.	Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224
Secondary	Overall Survival	Overall survival was defined as the time from randomization until death due to any cause. Here, number of participants analyzed was based on the number of participants who underwent death.	From start of study drug administration up to EOT (approximately 21 Months)
Secondary	Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	EORTC QLQ-C30 was a validated instrument used to measure QoL and assess symptoms and side effects of treatment and the impact on everyday life.The QLQ-C30 was composed of: A) 5 multi-item functioning scales(physical, role, social, emotional and cognitive), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a higher level of functioning and a better QoL. B) A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score range from 0 to 100 with a higher score representing a better QoL. C) 9 symptom scales(fatigue, nausea/vomiting,pain,financial impact/difficulties,appetite loss,diarrhea, constipation,sleep disturbance/insomnia and dyspnea), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a greater degree of symptoms and a worse QoL.	Baseline, 21 Months (EOT) up to follow-up